COMMUNIQUÉS West-GlobeNewswire

GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)
14/05/2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de [...]
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
14/05/2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and [...]
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
14/05/2025
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF [...]
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025 [...]
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results
14/05/2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025 [...]
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
14/05/2025
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial [...]
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
14/05/2025
Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced selection of IL15-superagonist as first payload to be delivered into tumors with [...]
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
14/05/2025
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year
14/05/2025
Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; [...]
Jasper Therapeutics to Present at Upcoming Investor Conferences
14/05/2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
14/05/2025
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. The report [...]
SS Innovations Reports First Quarter 2025 Financial Results
14/05/2025
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS [...]
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
14/05/2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of [...]
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
14/05/2025
Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that [...]
Precipio Announces its Q1-2025 Financial Results
14/05/2025
Conference call to follow tomorrow, May 15 at 5 PM EST NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its 10-Q report today. The following [...]
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
14/05/2025
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE) [...]
Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
14/05/2025
CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced [...]
RAMSAY SANTE : Résultats intermédiaires au 31 mars 2025
14/05/2025
COMMUNIQUÉ DE PRESSE Paris, le 14 mai 2025 Résultats intermédiaires au 31 mars 2025 Croissance de l'activité et contrôle des coûts compensent une tarification défavorable Le chiffre d’affaires non audité du groupe pour [...]

Pages